Overall, these studies and discrepancies between non-clinical and clinical results with sGC stimulators show that direct head-to-head comparison of sGC activators and sGC stimulators could be very rewarding and are needed to potentially identify the populations of CKD that benefit the most. This evidence concerns the gene SGCB and chronic kidney disease.